RELATING TO THE PROXY STATEMENT
FOR THE ANNUAL MEETING OF STOCKHOLDERS
To Be Held On June 27, 2019
On
April 30, 2019, Proteostasis Therapeutics, Inc. (the Company) filed its proxy statement relating to its 2019 Annual Meeting of Stockholders (the Proxy Statement) with the Securities and Exchange Commission, and made the
Proxy Statement available on the Internet on that same day. Subsequent to that date, the Board of Directors (the Board) of the Company appointed a new Class III director, Badrul A. Chowdhury, M.D. Ph.D. These additional materials
have been prepared to provide stockholders with information regarding the Companys new director that would have been included in the Proxy Statement had Dr. Chowdhury been appointed prior to the filing of the Proxy Statement. You are not
being asked to vote for or ratify the appointment of Dr. Chowdhury at the upcoming Annual Meeting, as the Class III directors are not being elected by Company stockholders at this meeting. These additional materials are being provided
solely for informational purposes.
Appointment of New Director
On May 12, 2019, the Board of Directors (the Board) elected Badrul A. Chowdhury, M.D. Ph.D., as a Class III director whose term will
expire at the Companys 2021 annual meeting of shareholders, effective immediately. The Board has determined that Dr. Chowdhury is independent within the meaning of the director independence standards of The Nasdaq Stock Market LLC and the
Securities and Exchange Commission.
Business Experience of Dr. Chowdhury
Badrul A. Chowdhury
, age 61, has served on our Board since May 2019. Dr. Chowdhury has served as Senior Vice President, Chief
Physician-Scientist, Respiratory Inflammation and Autoimmunity, Late Stage, Research and Development Biopharmaceuticals, AstraZeneca, (NYSE: AZN) since April 2019. Prior to that he was Senior Vice President, Research and Development AstraZeneca
Medimmune; Head of Respiratory Inflammation and Autoimmunity (RIA) Innovative Medicine Early Development at Medimmune, from April 2018 to April 2019. From August 1997 to April 2018, he was at the United States Food and Drug Administration (FDA)
where he held roles of increasing responsibility, including Director of the Division of Pulmonary, Allergy, and Rheumatology Products at the FDAs Center for Drug Evaluation and Research (CDER). Dr. Chowdhury has a M.B., B.S. in Medicine
from University of Dhaka, Dhaka Medical College, Bangladesh, and a Ph.D. in Immunology from Memorial University of Newfoundland, Canada. He completed his residency training in Internal Medicine at the Wayne State University School of Medicine,
Detroit, Michigan, and fellowship in Allergy and Immunology at the National Institutes of Healths, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, and is double board certified in Internal Medicine and Allergy and
Immunology. Our Board believes that Dr. Chowdhurys extensive clinical trial and regulatory strategy expertise at the FDA and with the pharmaceutical industry make him qualified to serve on the Board.